PHARMACODYNAMIC DEMONSTRATION OF IMMUNOLOGICAL TOLERANCE INDUCED BY KAN-101, A NOVEL LIVER-TARGETED THERAPY FOR COELIAC DISEASE, PERSISTS FOLLOWING DRUG CLEARANCE

Joseph Murray  ¹     Dina Wassaf  ²     Stephanie Morgan  ²     Stephan Kontos  ²     Kaela Goldstein  ²     Tom Thornley  ²     Kristie Grebe  ^2    
1 Mayo Clinic, Rochester, United States
² Anokion, Cambridge, United States

Topic
Hepatobiliary, IBD, Small Intestine & Nutrition

Session
Big steps for coeliac and short bowel

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)